Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial

Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A banner about NIH website updates and terminology during a stated transition was removed. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    1%
    Check dated 2026-11-07T12:25:36.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:24:36.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A sitewide banner announces updates and FAQs about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T15:48:18.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T15:37:13.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T15:36:48.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the usual study record content. The standard study details and navigation are not accessible on this page.
    Difference
    17%
    Check dated 2026-09-19T19:36:37.000Z thumbnail image

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.